New reports from the Massachusetts Biotechnology Council show a rebound in seed deals and IPO activity alongside warning signs in federal funding and early-stage capital. MassBio’s industry snapshot found the state’s biopharma workforce shrank 3% in 2025, NIH research funding dipped to $3.413 billion, and seed-stage VC fell sharply in the first half of 2026. Massachusetts tracked 21 seed deals in Q1–Q2 2026, but median early money moved downward as seed capital declined year-over-year. NIH funding fell to 2025 levels from 2024 and the number of NIH awards dropped, a “fewer shots on goal” signal highlighted by MassBio leadership. The report contrasts those headwinds with strong fundraising readouts, including $3.45 billion in VC in the first half of 2026 and the highest number of IPOs since 2021. MassBio described the environment as capable of sustaining a flywheel, but warned that reduced NIH awards and smaller seed rounds could erode the research base supporting future pipeline success. For biotech operators and investors, the message is clear: exits are improving while earlier translational and discovery funding remains vulnerable.